{"schema_version":"1.0","type":"article","title":"德國默克13億押降鐵針，換掉放血不換藥華藥","url":"https://drugnews.com.tw/articles/2026-10-24-merck-kgaa-silence-divesiran-polycythemia-vera-besremi.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-24-merck-kgaa-silence-divesiran-polycythemia-vera-besremi.md","lang":"zh-Hant","date":"2026-10-24","publish_at":"2026-10-24T08:00:00+08:00","updated_at":"2026-10-24","category":"商業分析系列","topic":"BD / 授權","tags":["真性紅血球增多症","放血","德國默克 Merck KGaA","divesiran","藥華藥 BESREMi"],"summary":"真性紅血球增多症病人要定期回醫院放血。德國默克 10/19 砸 13 億美元買下 Silence 的 divesiran：二期 88% 病人不用再放血、三個月打一針。它換掉的是放血，不是藥華藥的 BESREMi。","key_points":["降鐵類新藥（Takeda 的 Mimrylo、德國默克收購的 divesiran）會取代真性紅血球增多症的放血，但不會取代藥華藥的 BESREMi：到 2027 年 6 月公布時，藥華藥 2027 年 1–5 月累計合併營收年增仍會在 30% 以上。","德國默克（Merck KGaA）在 2026 年 10 月 19 日宣布以每單位 ADS 20 美元、約 13 億美元現金收購 Silence Therapeutics，核心是 siRNA 藥 divesiran，預計 2027 年第一季完成。","divesiran 二期 SANRECO（48 位病人）中 88% 在第 18–36 週不需放血（安慰劑 19%）；Takeda 的 Mimrylo 在 2026 年 8 月 28 日獲 FDA 核准，三期 VERIFY 中 76.9% 不需放血（安慰劑 32.9%），但需每週注射。"],"facts":[{"claim":"德國默克收購 Silence Therapeutics 交易總值（2026-10-19 宣布）","value":13,"unit":"億美元","as_of":"2026-10-19","source":"https://www.fiercebiotech.com/biotech/merck-kgaa-buys-silence-13b-deal-biotechs-blood-cancer-sirna-drug"},{"claim":"德國默克收購 Silence 每單位 ADS 現金價格","value":20,"unit":"美元","as_of":"2026-10-19","source":"https://www.fiercebiotech.com/biotech/merck-kgaa-buys-silence-13b-deal-biotechs-blood-cancer-sirna-drug"},{"claim":"德國默克收購 Silence 預計完成時間","value":"2027 年第一季","unit":"","as_of":"2026-10-19","source":"https://www.biopharmadive.com/news/merck-kgaa-rnai-13b-silence-buyout-blood-disorder-polycythemia-vera/833336/"},{"claim":"德國默克 2026 年 6 月收購 Bio-Techne 企業價值","value":113,"unit":"億美元","as_of":"2026-10-19","source":"https://qz.com/merck-kgaa-silence-therapeutics-acquisition-biotech-101926"},{"claim":"divesiran 二期 SANRECO 收案病人數","value":48,"unit":"人","as_of":"2026-08-10","source":"https://www.curetoday.com/view/divesiran-eliminates-need-for-phlebotomy-in-88-of-patients-with-polycythemia-vera"},{"claim":"SANRECO 第 18–36 週不需放血達標率：divesiran 組","value":88,"unit":"%","as_of":"2026-08-10","source":"https://www.curetoday.com/view/divesiran-eliminates-need-for-phlebotomy-in-88-of-patients-with-polycythemia-vera"},{"claim":"SANRECO 第 18–36 週不需放血達標率：安慰劑組","value":19,"unit":"%","as_of":"2026-08-10","source":"https://www.curetoday.com/view/divesiran-eliminates-need-for-phlebotomy-in-88-of-patients-with-polycythemia-vera"},{"claim":"SANRECO 每 12 週給藥組達標率","value":81.3,"unit":"%","as_of":"2026-08-10","source":"https://www.curetoday.com/view/divesiran-eliminates-need-for-phlebotomy-in-88-of-patients-with-polycythemia-vera"},{"claim":"SANRECO 第 0–36 週平均每人放血次數：divesiran 組","value":0.2,"unit":"次","as_of":"2026-08-10","source":"https://www.curetoday.com/view/divesiran-eliminates-need-for-phlebotomy-in-88-of-patients-with-polycythemia-vera"},{"claim":"SANRECO 第 0–36 週平均每人放血次數：安慰劑組","value":2.1,"unit":"次","as_of":"2026-08-10","source":"https://www.curetoday.com/view/divesiran-eliminates-need-for-phlebotomy-in-88-of-patients-with-polycythemia-vera"},{"claim":"Mimrylo（rusfertide）FDA 核准日","value":"2026-08-28","unit":"","as_of":"2026-08-28","source":"https://www.cancernetwork.com/view/fda-approves-rusfertide-in-polycythemia-vera"},{"claim":"Mimrylo 三期 VERIFY 收案病人數","value":293,"unit":"人","as_of":"2026-08-28","source":"https://www.takeda.com/en-us/newsroom/news-releases/2026/fda-approval-mimrylo/"},{"claim":"VERIFY 32 週內不需放血比例：Mimrylo 組","value":76.9,"unit":"%","as_of":"2026-08-28","source":"https://www.cancernetwork.com/view/fda-approves-rusfertide-in-polycythemia-vera"},{"claim":"VERIFY 32 週內不需放血比例：安慰劑組","value":32.9,"unit":"%","as_of":"2026-08-28","source":"https://www.cancernetwork.com/view/fda-approves-rusfertide-in-polycythemia-vera"},{"claim":"Mimrylo 注射部位反應發生率（仿單最常見不良反應）","value":56,"unit":"%","as_of":"2026-08-28","source":"https://www.takeda.com/en-us/newsroom/news-releases/2026/fda-approval-mimrylo/"},{"claim":"Jakafi 2025 年銷售額","value":31,"unit":"億美元","as_of":"2026-08-31","source":"https://www.fiercepharma.com/pharma/cusp-pharmaessentia-gains-fda-label-expansion-besremi"},{"claim":"藥華藥 2026 年 9 月合併營收","value":26.35,"unit":"億新台幣","as_of":"2026-10-06","source":"https://www.moneydj.com/kmdj/news/newsviewer.aspx?a=2b08dc30-0dfd-49b5-92d9-64fae652da38"},{"claim":"藥華藥 2026 年 9 月合併營收年增率","value":99.98,"unit":"%","as_of":"2026-10-06","source":"https://www.moneydj.com/kmdj/news/newsviewer.aspx?a=2b08dc30-0dfd-49b5-92d9-64fae652da38"},{"claim":"藥華藥 2026 年 1–9 月累計合併營收","value":197.37,"unit":"億新台幣","as_of":"2026-10-06","source":"https://news.cnyes.com/news/id/6619391"},{"claim":"藥華藥 2026 年 1–9 月累計合併營收年增率","value":83.54,"unit":"%","as_of":"2026-10-06","source":"https://news.cnyes.com/news/id/6619391"},{"claim":"BESREMi 美國 ET 適應症是 FDA 自哪一年以來首個 ET 新藥","value":1997,"unit":"年","as_of":"2026-08-31","source":"https://www.fiercepharma.com/pharma/cusp-pharmaessentia-gains-fda-label-expansion-besremi"},{"claim":"Ropeg（BESREMi）連續列入 NCCN 指引 PV 第一線的年數","value":4,"unit":"年","as_of":"2026-10-06","source":"https://news.cnyes.com/news/id/6619391"}],"sections":["01｜13 億美元，為什麼押在一顆二期藥？","02｜病在骨髓，藥卻打在肝臟","03｜每週一針對上三個月一針，Takeda 的領先只有三年","04｜台灣藥華藥：降鐵針搶不到的那一層","參考資料"],"references":[{"title":"Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win","source":"Fierce Biotech","date":"2026-10-19","url":"https://www.fiercebiotech.com/biotech/merck-kgaa-buys-silence-13b-deal-biotechs-blood-cancer-sirna-drug"},{"title":"Merck KGaA bets on RNAi with $1.3B Silence buyout","source":"BioPharma Dive","date":"2026-10-19","url":"https://www.biopharmadive.com/news/merck-kgaa-rnai-13b-silence-buyout-blood-disorder-polycythemia-vera/833336/"},{"title":"Merck KGaA to buy Silence Therapeutics for $1.3 billion","source":"Quartz","date":"2026-10-19","url":"https://qz.com/merck-kgaa-silence-therapeutics-acquisition-biotech-101926"},{"title":"Silence Therapeutics letter to investigators on Merck KGaA acquisition (Form DEFA14A, Ex. 99.4","source":"SEC","date":"2026-10-19","url":"https://www.sec.gov/Archives/edgar/data/0001479615/000119312526425238/d189864dex994.htm"},{"title":"Divesiran eliminates need for phlebotomy in 88% of patients with polycythemia vera","source":"CURE","date":"2026-08-10","url":"https://www.curetoday.com/view/divesiran-eliminates-need-for-phlebotomy-in-88-of-patients-with-polycythemia-vera"},{"title":"FDA Approves MIMRYLO (rusfertide) for Polycythemia Vera","source":"Takeda","date":"2026-08-28","url":"https://www.takeda.com/en-us/newsroom/news-releases/2026/fda-approval-mimrylo/"},{"title":"FDA approves rusfertide in polycythemia vera","source":"CancerNetwork","date":"2026-08-28","url":"https://www.cancernetwork.com/view/fda-approves-rusfertide-in-polycythemia-vera"},{"title":"On the 'cusp,' PharmaEssentia gains FDA label expansion for Besremi","source":"Fierce Pharma","date":"2026-08-31","url":"https://www.fiercepharma.com/pharma/cusp-pharmaessentia-gains-fda-label-expansion-besremi"},{"title":"藥華藥PV及ET雙引擎持續發威 9月營收年增1倍續創單月高","source":"鉅亨網","date":"2026-10-06","url":"https://news.cnyes.com/news/id/6619391"},{"title":"藥華藥 115年9月營收26.35億、年增99.98%","source":"MoneyDJ理財網","date":"2026-10-06","url":"https://www.moneydj.com/kmdj/news/newsviewer.aspx?a=2b08dc30-0dfd-49b5-92d9-64fae652da38"},{"title":"Besremi (ropeginterferon alfa-2b) prescribing information","source":"Drugs.com","date":"2026-10-20","url":"https://www.drugs.com/pro/besremi.html"}],"images":[{"alt":"圖1｜三種藥打在三個位置","url":"https://drugnews.com.tw/assets/articles/merck-kgaa-silence-divesiran-polycythemia-vera-besremi/figure-01.png"},{"alt":"圖2｜不用放血的病人比例","url":"https://drugnews.com.tw/assets/articles/merck-kgaa-silence-divesiran-polycythemia-vera-besremi/figure-02.png"},{"alt":"圖3｜PV 三種藥的同一把尺","url":"https://drugnews.com.tw/assets/articles/merck-kgaa-silence-divesiran-polycythemia-vera-besremi/figure-03.png"},{"alt":"圖4｜從放血到降鐵針的時間線","url":"https://drugnews.com.tw/assets/articles/merck-kgaa-silence-divesiran-polycythemia-vera-besremi/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/merck-kgaa-silence-divesiran-polycythemia-vera-besremi/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-24）。德國默克13億押降鐵針，換掉放血不換藥華藥。https://drugnews.com.tw/articles/2026-10-24-merck-kgaa-silence-divesiran-polycythemia-vera-besremi.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}